Tackling the Serious Global Challenges in Infectious Disease

Appili was created to deliver innovative drug development programs for unmet patient needs across a broad spectrum of infectious diseases

Appili Therapeutics Infectiou Disease Drug Development Program

Advancing infectious disease drug development programs to provide solutions to patients, doctors, and society.

Leadership team skilled in advancing programs with upside potential

Active partnering and in-licensing efforts to expand clinical programs and accelerate commercialization

Appili Therapeutics: Innovation Across a Broad Spectrum of Anti-Infectives

LATEST NEWS & EVENTS

Appili Therapeutics Reports Fiscal Year 2021 Financial and Operational Results Provides Update on Strategy for Fiscal 2022
06/24/2021
Appili Therapeutics Inc. Expands PRESECO Clinical Trial of Avigan®/Reeqonus™ for Mild-to-Moderate COVID-19 Patients into Mexico and Brazil
06/17/2021
Independent Data Safety Monitoring Board Recommends Appili Therapeutics Complete Its Phase 3 Avigan®/Reeqonus™ Trial for Mild-to-Moderate COVID-19 Patients
05/17/2021